4.5 Article

Ontogeny of phencyclidine and apomorphine-induced startle gating deficits in rats

Journal

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
Volume 65, Issue 3, Pages 449-457

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0091-3057(99)00217-8

Keywords

apomorphine; development; neurotoxicity; phencyclidine; prepulse inhibition; schizophrenia; sensorimotor; startle

Funding

  1. NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001436, R01MH053484] Funding Source: NIH RePORTER
  2. NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002925] Funding Source: NIH RePORTER
  3. NIDA NIH HHS [DA02925] Funding Source: Medline
  4. NIMH NIH HHS [MH01436, MH53484] Funding Source: Medline

Ask authors/readers for more resources

NMDA antagonists and dopamine (DA) agonists produce neuropathological and/or behavioral changes in rats that may model specific abnormalities in schizophrenia patients. In adult rats. Nh IDA antagonists and DA agonists disrupt sensorimotor gating-measured by prepulse inhibition (PPI)-modeling PPI deficits in schizophrenia patients. In addition, high doses of NMDA antagonists produce Limbic system pathology that may model neuropathology in schizophrenia patients. We examined these behavioral and neuropathological models across development in rats. Both the NMDA antagonist phencyclidine (PCP) and the DA agonist apomorphine disrupted PPI in 16 day pups, demonstrating early developmental functionality in substrates regulating these drug effects on PPI. In contrast, PCP neurotoxicity was evident only in adult rats. Brain mechanisms responsible for the PCP disruption of PPI, and PCP-induced neurotoxicity, are dissociable across development. (C) 2000 Elsevier Science Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available